Helix BioPharma (TSE:HBP) Announces Quarterly Earnings Results

Helix BioPharma (TSE:HBP) issued its earnings results on Friday. The biopharmaceutical company reported C($0.01) earnings per share (EPS) for the quarter, FiscalAI reports.

Helix BioPharma Price Performance

Shares of Helix BioPharma stock opened at C$0.99 on Friday. The company has a current ratio of 0.45, a quick ratio of 1.03 and a debt-to-equity ratio of 2.44. Helix BioPharma has a 12-month low of C$0.82 and a 12-month high of C$2.60. The company has a market cap of C$75.61 million, a P/E ratio of -24.75 and a beta of 1.15. The company’s fifty day simple moving average is C$1.29 and its two-hundred day simple moving average is C$1.63.

Helix BioPharma Company Profile

Helix BioPharma Corp. is a clinical-stage oncology company focused on developing therapies for underserved patient populations with difficult-to-treat cancers. The Company’s pipeline is led by L-DOS47, a clinical-stage antibody-enzyme conjugate being developed as a combination therapy for non-small cell lung cancer (NSCLC). Additional pipeline candidates include LEUMUNA¿, a pre-IND oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA¿, a pre-IND gemcitabine prodrug for advanced solid tumors.